GlassScriptPhysician profile
Michelle A Chico
NPI 1053504662
$12,373.63
in general payments reported to CMS, 2019-2025
29 companies · $3,065 in 2025
The $3,065 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $1,467 · 2021: $1,615 · 2022: $1,658 · 2023: $2,145 · 2024: $1,192 · 2025: $3,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,837 · Travel and Lodging: $1,003 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $450 · Consulting Fee: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,836.76 |
| Travel and Lodging | $1,002.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $450.00 |
| Consulting Fee | $112.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,597.89 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Dexcom, INC. | $1,659.52 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $1,208.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,054.70 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $820.80 | 2019-2022 | |
| Cequr Corporation | $630.75 | 2025 | Cequr Simplicity |
| Amarin Pharma, INC. | $520.73 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $476.38 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $413.25 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.90 | 2019-2025 | Jardiance, Synjardy |
| Medtronic Minimed, INC. | $350.53 | 2019-2020 | |
| Esperion Therapeutics, INC. | $317.17 | 2021-2025 | Nexletol |
| Corcept Therapeutics | $315.18 | 2021-2025 | Korlym |
| Amgen INC. | $237.27 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $231.66 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $178.65 | 2020-2023 | Freestyle Libre 3 |
| Grt US Holding, INC. | $178.25 | 2020-2022 | |
| Abbvie INC. | $139.66 | 2020-2025 | Synthroid |
| Novartis Pharmaceuticals Corporation | $125.69 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $111.80 | 2021-2025 | Gvoke Hypopen |
| Insulet Corporation | $108.35 | 2019-2025 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $58.73 | 2020-2021 | |
| Erbe USA INC | $50.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.40 | 2021 | |
| Averitas Pharma INC. | $37.78 | 2024 | Qutenza |
| Horizon Therapeutics Plc | $37.52 | 2022-2023 | Tepezza |
| Shire North American Group INC | $36.58 | 2019 | |
| Ascendis Pharma Endocrinology INC | $16.68 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $14.60 | 2025 | Twiist |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Chico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.